chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Unspecific adverse event; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Unspecific adverse event) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Unspecific adverse event). At the time of the report, VACCINATION COMPLICATION (Unspecific adverse event) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications are provided by reporter. No treatment medication are provided by reporter.  Caller did not specify any adverse event.
Rash over body within five minutes of injection. Given Benadryl and observed foe two hours
Severe flu like symtoms. Body aches, fever, headache. Also, throughout the night there was an extremely strong sensation to urinate, however, it was very difficult to urinate.
Mild allergic reaction consisting of itchy eyes, skin, and scalp. Minor hive-like bumps appeared on legs. Self-administered Benadryl antihistamine tablet to control the allergic reaction.
feeling unwell; Chills; extreme body aches; joint pain; headache; nausea; fever; injection site swelling/redness/pain; injection site swelling/redness/pain; injection site swelling/redness/pain; This is a spontaneous report from a contactable other hcp.   A 33-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot# unknown), via an unspecified route of administration arm left single dose on 22Jan2021 16:15 for covid-19 immunisation. Medical history included hypothyroidism, drug hypersensitivity to penicillin, ceclor, bactrim, covid-19. Concomitant medications included letrozole, levothyroxine. No other vaccine was received in four weeks.  The patient experienced feeling unwell on 23Jan2021 13:30, chills on 23Jan2021 13:30, extreme body aches on 23Jan2021 13:30, joint pain on 23Jan2021 13:30, headache on 23Jan2021 13:30, nausea on 23Jan2021 13:30, fever on 23Jan2021 13:30, injection site swelling/redness/pain on 23Jan2021 13:30. No treatment received. The outcome was recovering. Information on the Lot/Batch Number has been requested.
12 day p/vax t100-101, neck & jaws swollen;encouraged to seek MD car & dx no MD made-PC 29AUG96 s/s much improved w/residual swelling;
erythematous maculo papular rash on face;few areas on anterior chest;tender subauricular & anterior cervical lymphadenopathy;
The guy stabbed me pretty good with the needle when he administered it to me. It is my Left Upper Arm.
Pt said she experienced body aches, fever, and chills the evening after she received the shot. She said that her arm was warm to the touch but no redness in the area. She said that the symptoms persisted until Sunday 2/18/2018 evening.
This spontaneous report was received from a healthcare worker and refers to an unspecified number of patients of unknown age and gender. On an unknown dates, the patients were vaccinated with an unspecified doses of improperly stored GARDASIL 9 lot # M023169 and expiration date 13-JUN-2018 (dose and frequency was not reported) for prophylaxis. No adverse effect reported. This is one of two reports received from the same reporter.; Sender's Comments: US-009507513-1708USA012429:
Small bump around injection site; Arm hurts; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site swelling in a 72-year-old female patient who received Herpes zoster (Shingrix) (batch number 5YR3P, expiry date 17-JUN-2024) for prophylaxis.   On 14-MAR-2023, the patient received the 1st dose of Shingrix (intramuscular, left arm). On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site swelling (Verbatim: Small bump around injection site) and pain in arm (Verbatim: Arm hurts). The outcome of the injection site swelling and pain in arm were not resolved.   It was unknown if the reporter considered the injection site swelling and pain in arm to be related to Shingrix.     It was unknown if the company considered the injection site swelling and pain in arm to be related to Shingrix.   Additional Information: GSK Receipt Date: 06-JUN-2023 The reporter was a pharmacy intern called on behalf of a patient that called the pharmacy to report that she received dose of Shingrix and her arm still hurt and there was a small bump forming around the injection site. The reporter had no further information to report about this event. The reporter consented to follow up. Consent to follow up with pharmacy about this was obtained.
This spontaneous report was received from a physician via a company representative concerning a female patient of unknown age. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (lot number, expiry date, dose and route unspecified). No concomitant medications were reported. On an unknown date, the patient experienced shingles after receiving ZOSTAVAX. The patient sought medical attention (doctor visit). The patient was treated with unspecified antiviral medication and unspecified pain medication. No lab tests were performed. The outcome of the event was unknown. The relatedness for the event was unknown for ZOSTAVAX. Additional information has been requested.
Two days after the administration of the Pfizer vaccine, started with generalized muscular pain, inflammation in the wrists and hands. decreased function when moving and doing any exercise like opening a door.  On two occasions went to the ER routine exams have been done and laboratories are normal at the PCP's office.  But the clinical picture worsened daily.
This spontaneous case was initially received on 29-Sep-2015. The case report was received from a Health Professional and concerns a patient with unknown age and gender. Suspect drug (s), timing and conditions surrounding the onset of reaction (s)/ event (s): The patient received AFLURIA for indication not reported on unknown dates, Batch no: not provided, Route of administration: Unknown, Dose: no information provided. Additional suspect drug (s): No additional drugs suspected. Reaction (s)/ event (s) and outcome: On an unknown date, the patient experienced an Unspecified reaction on an unspecified date to AFLURIA (non serious, outcome: Unknown).
Redness, hardness and warmth at the injection site about one inch in width, painless. Symptom started 8 days after the injection.
I had to drive home, I was very woozy. I felt like I was drugged. I barely made in my home. I was in bed for 24 hours. I had Headache shaking chills. On Monday I was able to move, but I felt horrible. It has lasted for the entire month. Fatigue, congestion, headache, and I had very little appetite. During that same time, I was experiencing inflammation all over, my feet swelled. I was barely able to walk. My veins were swelling. I got severe constipation. I still felt bad after two months, but I was getting better. I don't get headaches, but they were constantly coming. I went to several urgent care. I did get the booster but it was not as harsh as the 2nd dose.
I felt weak/drained within about an hour of vaccination on April 16. On April 17 I felt pain across my body at the level of the skin, including on my scalp. I was extremely cold without a fever, but later developed a fever with e a temperature of 100.7. The symptoms subsided at approximately 5:30 PM on the same day.
WHOLE ARM HURT, FELT "NUMB" AND WAS NOT ABLE TO MOVE IT FOR 1 WEEK.
This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications. On 14-MAR-2018, the patient was vaccinated with GARDASIL 9 lot number N021475 with expiration date on 31-JAN-2020 (strength, dose, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis. The administered dose of the vaccine experienced a temperature excursion in the range between 32°F up to 35°F for 270 minutes and 47°F to 77°F for 75 minutes, as recorded by a data logger. The vaccine had not had any previous temperature excursions. There was no adverse effect reported. No product quality complaint was involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1805USA003078.
G47.33 ADULT OBSTRUCTIVE SLEEP APNEA, MILD 4/21/2023 ESSENTIAL HTN RENAL MASS G47.33 ADULT OBSTRUCTIVE SLEEP APNEA, MILD 4/21/2023 RENAL MASS
Information has been received from the VAERS database via journalist. This spontaneous report as received from a other refers to a patient of unknown age. The patient was vaccinated with lot # (656412/1476F) ZOSTAVAX on 17-APR-2007. No other co-suspects were reported. No concomitant medications were reported. On an unknown date the patient experienced herpes zoster. No treatment information was reported. The outcome of herpes zoster is unknown. The relatedness for herpes zoster is unknown for ZOSTAVAX. Additional information is not expected.
This spontaneous report has been received from a pharmacist and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On an unknown date, the patient was vaccinated with dose of improperly stored VAQTA injection (strength, dose, route of administration, lot # and expiration date were not reported). No adverse effects were reported. The vaccine experienced a temperature excursions between 32 Fahrenheit degrees (F) and 36 (F) for 3 hours and 30 minutes and below 32 (F) (31 (F)) for 1 hour and 30 minutes, which were detected by a digital data logger. There was no previous temperature excursion. No product quality complaint was involved.  Additional information has been requested.
This spontaneous report as received from a medical assistant refers to multiple unspecified patients of unknown age and gender. The concurrent conditions, drug reactions/allergies and medical history of the patients were not reported. On unknown dates, the patients were vaccinated with doses of improperly stored PNEUMOVAX 23 with lot number M006141 and expiration date of 28-MAY-2017 (strength, route of administration, anatomical location and dose were unknown), which were stored at a maximum of 60 Fahrenheit degrees (F) for 24 hours and a minimum of 29.3 degree F for 1.5 hours (14 cycles below 32 degree F). There was a previous temperature excursion described as below 32 degree F off and on for a week, several occasions stated as 50 minutes, 45 minutes, 40 minutes, 55 minutes, 1 hour and 15 minutes, 50 minutes, 35 minutes, 35 minutes, 1 hour and 35 minutes, 2 hours and 15 minutes, 45 minutes, 30 minutes and 55 minutes. The temperature excursions were detected by a data logger. No concomitant therapies nor adverse effect were reported. No product quality complaint was involved. This is one of several cases from the same reporter. Additional information has been requested.
After receiving Pfizer dose 2 pt. reported hives 12 minutes after injection. Pt reports mild throat itchiness. Negative for orthostasis discharged after completed evaluation, released into care of mother. DC V/S  T:1316, HR: 82, R:18, BP: 122/78, Spo2: 100%.
Father reports that the day after getting vaccine patient began experiencing fatigue, muscle weakness, nausea, loss of appetite, sore throat. Vomiting became worse later in the week and improved 10-15 Saturday after being seen in the ER and being given ondansetron.  Patient is still coughing but feeling overall better. Improved fatigue and appetite is returning now, but still nauseous.
Severe burning on entire left side of body; Headache; Lethargy; Brain fog; This is a spontaneous report from a contactable reporter (consumer or other non HCP). The reporter is the patient.   A 64-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in left arm, administration date an unknown date in Sep2021 (Lot number: unknown) at the age of 64 years as dose 1, single for COVID-19 immunisation. Relevant medical history included Fibromyalgia (unspecified if ongoing) and Allergy to intravenous contrast media (unspecified if ongoing). Concomitant medications were not reported. Past drug history included Tequin, reaction included Drug allergy, Known allergies Tequine; Nubaine, reaction included Drug allergy, Known allergies Nubane and Panadol, reaction included Drug allergy, Known allergies Ipanadol.  The following information was reported BURNING SENSATION (non-serious) with onset an unknown date in Sep2021, outcome recovered with sequelae (an unknown date in 2021); HEADACHE (non-serious) with onset an unknown date in Sep2021, outcome recovered with sequelae (an unknown date in 2021); LETHARGY (non-serious) with onset an unknown date in Sep2021, outcome recovered with sequelae (an unknown date in 2021); FEELING ABNORMAL (non-serious) with onset an unknown date in Sep2021, outcome recovered with sequelae (an unknown date in 2021). Therapeutic measures were not taken as a result of burning sensation, headache, lethargy, and feeling abnormal.  It was reported that the patient received bnt162b2 (BNT162B2) at 17:00. The patient did not receive any other vaccines within four weeks prior to the prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.   The lot number for BNT162b2 was not provided and will be requested during follow up.
This case was reported by a physician via sales rep and described the occurrence of intussusception in a 4-month-old male patient who received ROTARIX. On an unknown date, the patient received the 2nd dose of ROTARIX (oral) 1 ml. On an unknown date, an unknown time after receiving ROTARIX oral suspension, the patient experienced intussusception (serious criteria GSK medically significant), blood in stool (serious criteria GSK medically significant) and dehydration. On an unknown date, the outcome of the intussusception, blood in stool and dehydration were unknown. The reporter considered the intussusception, blood in stool and dehydration to be possibly related to ROTARIX oral suspension. Additional details were provided as follows: The age at vaccination was not provided. Limited information was provided by the sales representative from the physician. The sales representative reported that the other vaccines were given to the patient at the time of the ROTARIX, but the vaccines were unknown. The patient went to the physician's office and to the hospital. The patient did not have surgery.
This spontaneous report as received from a pharmacist refers to a patient of unknown age. It was reported that the patient was vaccinated with PNEUMOVAX 23 (dose, frequency, route and lot number unknown) on 05-SEP-2012, which had expired on 31-AUG-2012. No concomitant medications were reported. No adverse effect was reported. Additional information is not expected.
2-3 weeks after COVID vaccination, patient presented to hospital with anemia and thrombocytopenia and intracranial hemorrhage.  L axillary mass (same side as Pfizer vaccine admin site) found on exam. Bone marrow biopsy demonstrated Burkitt's Lymphoma. He is undergoing treatment at hospital
6 mo infant rec'd HIBTITER/DTP/OPV on 20DEC90. Hospitalized on 4JAN91 w/H. Influenza Meningitis. Tx Ceftrixone & did well.
PATIENT RECEIVED FLUCELVAX WHILE UNDER THE AGE OF 18 WITH NO ADVERSE EVENT REPORTED.
3x2cm area of raised indurated erythema in area of lt bicep, anteriorly sl bicepital tenderness;resolved p/4 days small area of sl erythema on 18NOV98 @ site;
mom states pt played w/no problems p/vax pt starting c/o pain p/waking up from nap;pt c/o of pain in lt thigh all noc & this AM;
Initial and follow-up information has been received from a nurse practitioner and a certified medical assistant concerning a 25 year old female student (weight 193#, height 63") with penicillin allergy who on approximately 14-MAR-2008 was vaccinated with her first dose of Gardasil intramuscularly (lot number and site of administration not reported). Concomitant medication was not reported. About an hour after being vaccinated the patient developed a full body rash.  The patient sought unspecified medical attention on an unspecified date.  The patient has recovered.  Additional information has been requested. This is in follow-up to report(s) previously submitted on 4/14/2008.  On 14-MAR-2008 at 11 am, within 45 minutes (also reported as about an hour) after being vaccinated, the patient developed a full body rash. The patient returned to the clinic for evaluation and the rash was already starting to disappear. On an unspecified date, the patient recovered. Additional information is not expected.
Patient reports swelling  and redness at the injection site. She reports at both the injection site and all over her body. She also reports having experienced welts. She stated the reaction started approximately 45 minutes to 1 hour after receiving the vaccines. She reports that the events did not decrease in severity until 10/26/2020. When I spoke to the patient on 10/26/20 she had not treated the reactions, although I recommended diphenhydramine or hydroxyzine.
resp distress;rx solumedrol, DPH, FFT w/ proventyl;
Was given valacyclovir to take 4 hrs after the vaccine and took 2 pills, then 2 more 12 hrs later and I still feel a blister forming on my bottom lip. The 2nd dose cause blisters to form all over and into my throat, so we'll see. Using Abreva now
84 year old female, presented to ED for abdominal pain, nausea vomiting and had eaten a ham sandwich prior to symptom onset.  In the ED she was normothermic and initially hypertensive. TRACS consulted in ER. CT abd/pelvis showing mild ileal wall thickening suggestive of enteritis, no obstruction or other acute abnormality. Overnight had worsening hypotension, required bipap support and rising lactate.  She had worsening pressor requirements  and diagnosed with visceral ischemia, vascular consulted. Trauma surgery, Pulmonary medicine and Vascular physicians deemed patient poor prognosis and high risk and patient taken to OR for an SMA embolectomy  ex-lap, returned to CVCU hemodynamically unstable and passed away.
Chills, aching joints and low grade fever at 7pm; hives covering body by 11pm; doctor visit 10/18/09 with suggestion of Benadryl; Benadryl administered at 12:30pm and 6pm 10/18/09 - 8pm, hives still prominent, Benadryl no effect, lips began to swell rapidly; ER visit 9pm 10/18/09 - received prescription of rotinidine for 2x/day for 4 days; 10/19/09 hives 50% better, 5pm fever of 102; 7pm temp at 98.6 after a 5pm dose of Motrin; 10/20/09 hives more blotchy, bottom of feet swollen from hives, hard to walk, no fever, patient much more comfortable.
A pharmacist reported that several elderly residents of a nursing home received and injection in October, 1999 and subsequently developed flu-like symptoms. The reporter was unable to specify the number of pt who experienced this event. Additional reports will be generated when identify information is provided.
A little more than one day after vaccination my heart started to flutter(skip) and had a dull pain.  This went on for about 3 days.
LEFT SIDED PAIN; ANKLE PAIN; HURTING OF UPPER THIGH; HURTING OF LEGS; MUSCLE ACHES; This spontaneous report received from a consumer concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, and  expiry: UNKNOWN) dose was not reported, administered on 13-APR-2021 for prophylactic vaccination.  No concomitant medications were reported.  On 13-APR-2021, the subject experienced left sided pain. On 13-APR-2021, the subject experienced ankle pain. On 13-APR-2021, the subject experienced hurting of upper thigh. On 13-APR-2021, the subject experienced hurting of legs. On 13-APR-2021, the subject experienced muscle aches. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from left sided pain, ankle pain, hurting of upper thigh, hurting of legs, and muscle aches. This report was non-serious.
Immediately after receiving a second dose of Pfizer /COVID vaccine he began to feel pain and thought it was expected so did not mention it to the technician at local pharmacy.  After a feeling he had waited a reasonable( amount of time, he came in to see Dr. to be evaluated on 3/18/22. He has significant pain with certain ROM, especially with added weight of lifting objects such as groceries, etc.
I started getting dizzy after the shot, I started vomiting and bad bowel movements for 3 days. I also started having chest pain and increased heart rate. By that Monday, my heart rate was getting very high, and I was very dehydrated. On that Wednesday I had very bad chest pains with radiation. The next day I called the doctor's office and they thought it was a pulled muscle. I was given steroids'; muscle relaxers and the chest pain didn't get better. I then went to back to the doctor for a follow up and my results came back with clots. They sent me for a CT of my chest, and it didn't show clots. It was irregular heartbeats but has gotten a little better. I'm getting an echo cardiogram. The doctor thinks it's from me having COVID, I get very tired in the mornings.
This spontaneous report as received from a healthcare worker refers to a patient of unknown age. The patient was vaccinated with the first dose of GARDASIL (dose and lot # not reported) on 21-JUN-2011, the second dose of GARDASIL (dose and lot # not reported) on 31-AUG-2011 and was in the office "today" (19-APR-2013) (dose and lot # not reported) to receive the third dose of GARDASIL. No adverse event reported. It was unspecified if the patient had sought medical attention. Additional information has been requested.
1 week post injection developed a red, hot swollen area at injection site that lasted 1 week.
Rash, nerve pains, swollen lymph node in groin, itching, fatigue and tiredness. So far has lasted a week.
mom called office & stated pt devel hives 50 mins p/vax from head to toe & had a welt @ the HIB site on the lt thigh; advised to see MD immed; mom refused monitered @ home & administered DPH on advise of MD;
Headache, Seizures, UrticariaPruritus & NauseaVomiting Narrative:  NORMALLY HAVE SEIZURES EVERY EVENING, BUT THIS SEIZURE ABOUT 5.5 HRS POST VACCINE WAS MUCH MORE SEVERE WITH "EYES ROLLING IN BACK OF HEAD" AND FELT "IN A DAZE". TOOK AN EXTRA DOSE OF CLONAZIPAM 1 MG
That evening , started getting feverish and had temperature fluctuations, night sweats, body was sore all over.  Then the next day notied that my eyesite in my left eye seemed off- noted I had floaters and could not see as well as previously.   I assume this is a flare up of Toxoplasmosis as the eye symptoms are the same.
Patient had episodes of dizziness prompting him to be seen.  Was admitted and found to be COVID positive